The FDA released a second batch of its National Priority (commissioner) vouchers, speeding review pathways for selected drug candidates, and the administration simultaneously announced deals with Eli Lilly and Novo Nordisk to cut prices on popular weight‑loss medicines. The vouchers guarantee accelerated regulatory review windows; the White House accord will lower out‑of‑pocket costs for some Medicare beneficiaries and tie into ‘most‑favored nation’ pricing commitments. The coordinated actions link regulatory incentives to pricing concessions — a novel policy mix that pharma companies and payors will parse for precedent and commercial impact. Stakeholders should track which pending submissions use the vouchers and how the pricing terms reshape market access dynamics for GLP‑1 franchises.